Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Trading, I would say $26 is a likely case scenario, not worst, case for a buyout currently. The problem with scenarios, such as MP's projecting out all possible cancers treated by ADXS and putting a value on them, is that the ONLY construct we have currently in late stage trials is AXAL. Kite's sale was based on projected sales given their late stage trials and awaiting an FDA decision. For us to get all our other constructs to late stage, think about how much more dilution there would have to be to fund the trials and at our low stock price shareholder value would get hammered further, coupled with the execution missteps we have seen by ADXS, I say sell the company now for $20-something and let the experts take it from there and get it to market faster.